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Abstract: Psoriasis is a common, chronic inflammatory skin disease which is associated with 
a number of significant co-morbidities including: impairment of quality of life; cardiovascular 
disease; and a seronegative arthritis known as psoriatic arthritis. Our understanding of the patho-
genesis of psoriasis has developed at a remarkable rate in recent years. These new insights have 
significantly changed our perception of the condition and have led to the development of several 
new treatment strategies. Biological agents have proved a major step forward in therapeutic 
options for psoriasis. The ability to clear, or almost clear, cutaneous disease has changed the 
outcomes and expectations of many patients with this disease. The impact on both physical and 
psychological health may be great. This review covers the clinical features and management of 
psoriasis with specific reference to new therapeutic options.
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Introduction
Understanding the pathogenesis of psoriasis has developed at a remarkable rate 
over the last 20–30 years. This has provided significant changes in our percep-
tion of the condition, distinctions between subtle variants, and the response to 
treatment.
Biological agents have proved to be a major step forward in the therapeutic options 
for psoriasis. The ability to clear, or almost clear, cutaneous disease has changed the 
outcomes and expectations of many patients with this severe disease.
This review covers the clinical features and management of psoriasis with specific 
reference to new therapeutic options.
Clinical features of psoriasis
Psoriasis is an immune-mediated inflammatory disease which is currently incurable 
and occurs in 2%–3% of the population of the United Kingdom (UK).1 In early-onset 
psoriasis, developing before the age of 40 years (Type 1 psoriasis)2 and accounting 
for over 75% of patients, genetic predisposition in conjunction with an environmental 
trigger, such as infection or stress, is important for disease expression.1
Psoriasis can be a highly disabling disease which may impact significantly on a 
patient’s quality of life (QoL).3 Depression is significantly higher in sufferers than in 
the general population who have an increased incidence of suicidal ideation.4 Stud-
ies have revealed a reduction in QoL in patients with psoriasis which is comparable 
to patients with diabetes, heart disease and cancer.5 These factors may result in poor 
compliance with treatment and a further deterioration in psoriasis.Clinical, Cosmetic and Investigational Dermatology 2010:3 26
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Chronic plaque psoriasis and other 
clinical phenotypes
Several clinical phenotypes of psoriasis are recognized, with 
chronic plaque (psoriasis vulgaris) accounting for 90% of 
cases.1
1.  In chronic plaque psoriasis well demarcated papulosqua-
mous plaques occur in a symmetrical distribution com-
monly over the extensor surfaces of elbows and knees. 
Involvement of the scalp (typically within the hairline), 
lower back and umbilicus is also common. Lesions are 
typically red or salmon pink in color and covered by 
white or silver scale. The Koebner phenomenon is well 
recognized with psoriatic disease developing at sites of 
trauma or pressure.1
Other variants of the disease include inverse, guttate, pustular, 
and erythrodermic psoriasis.
2.  Inverse psoriasis presents in a flexural distribution; the 
principle difference between chronic plaque and flexural 
psoriasis is a relative lack of scale.
3.  Guttate psoriasis presents with characteristic erythema-
tous, scaly, ‘tear drop’ like papules widely distributed 
over the body as an acute eruption in the context of 
Group A beta-hemolytic streptococcal infection. Guttate 
psoriasis is usually self limiting. Long term approxi-
mately 1/3 of patients will develop chronic plaque 
psoriasis.6
4.  Generalized pustular psoriasis (von Zumbusch psoriasis) 
is a rapidly progressive disease presenting with tender, 
sterile pustules associated with widespread erythema. 
The patient is unwell and clinically may have fever and 
lymphadenopathy. Cardiovascular compromise can 
ensue, particularly in those with limited cardiovascular 
reserve. Isolated acral pustules are characteristic of pal-
moplantar pustulosis and probably represents a separate 
disease.7
5.  Erythrodermic psoriasis can occur de novo or on a 
background of chronic psoriasis; patients present 
with erythema involving more than 90% body sur-
face area associated with fever, malaise and systemic 
illness.
Nail disease
Nail changes include: pitting; oncolysis; oil drop sign; subungal 
hyperkeratosis; and dystrophy. Up to 50% of patients with pso-
riasis will demonstrate nail changes. For patients with psoriatic 
arthritis this figure may be as high as 80%.8
The importance of nail disease in the context of 
psoriatic arthritis is an area of intense research; the 
significance of entheseal disease appearing pivotal in 
disease development.9
Psoriatic arthritis
Incidence of psoriatic arthritis amongst patients with psoria-
sis may be as high as 25%,10 and may pre-date the psoriatic 
arthritis by 12 years or more.11
Features of psoriatic arthritis include persistent joint pain, 
early morning stiffness, dactylitis, and enthesitis. Dactylitis 
is associated with progressive joint disease.12 A significant 
challenge in managing psoriatic arthritis is identifying the 
disease early, so as to reduce the risk of deformity.
Seminal work by Moll and Wright identified 5 patterns 
of disease: asymmetric arthritis; distal interphalangeal joint 
arthritis only; symmetrical arthritis – rheumatoid like and 
spondyloarthropathy.13 More recent work has provided clearer 
diagnostic criteria via the Classification Criteria for Psoriatic 
Arthritis (CASPAR).14
Co-morbidities
Research over recent years has highlighted that psoriasis is 
associated with other immune mediated inflammatory condi-
tions including inflammatory bowel disease, and ankylosing 
spondylitis and cardiovascular disease.15–17
The risk of significant psoriasis-associated co-morbidities 
may prove a highly relevant point in rationalizing the treat-
ment algorithm for patients with psoriasis. Reversibility of 
some or all of the clinical phenotypes, with systemic therapy, 
would demand a more aggressive approach to therapy and 
perhaps early intervention.
Management strategies
Treatment for psoriasis must be tailored to meet the needs 
of the individual based on site and severity. Traditionally 
a minimum body surface area (BSA) of 10% was deemed 
necessary to consider systemic therapy.18 This may be lower 
where cosmetically sensitive or functionally limiting disease 
is present. A minimum psoriasis area and severity index 
(PASI) value is frequently used in national guidelines and 
clinical trials (eg, PASI  10).19
Topical therapy
For mild or moderate disease, affecting relatively small areas, 
a topical regimen may be sufficient to control the disease. The 
use of corticosteroids, vitamin D analogues, keratinolytics, 
tazarotene, anthracyclines and coal tar preparations have 
provided the topical options for treatment. New strategies 
for topical therapies include:Clinical, Cosmetic and Investigational Dermatology 2010:3 27
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Calcipotriol and betamethasone 
dipropionate
Over the last 7 years combination calcipotriol and beta-
methasone dipropionate have gained wide acceptance as 
a useful combination therapy. This has been shown to be 
more effective than either calcipotriol or betamethasone 
dipropionate alone.20 It is well tolerated as part of a 4-week 
cyclical regimen with calcipotriol.21
More recently the use of calcipotriol and betamethasone 
dipropionate in a gel formulation has proved a useful addi-
tion in treatment of scalp psoriasis. Randomized, double-
blind controlled trials have shown significant benefit from 
combined therapy preparations with one study reporting 92% 
achieving control over 52 weeks.22,23
Calcineurin inhibitors
The role of calcineurin inhibitors is limited to facial and 
intertriginous disease. A study using tacrolimus 0.1% 
ointment to treat facial and intertriginous psoriasis of 167 
patients for 8 weeks resulted in clear or almost clear in 65%, 
as compared to 31% in the placebo group.24 Similar results 
were demonstrated with pimecrolimus.25 The main drawback 
of such treatment is burning and stinging on initiation of 
therapy. Cutaneous malignancy has not been observed in 
clinical trials.26
Ultraviolet therapy
Where topical therapy fails to provide suitable control, or the 
lesions are too widely distributed for topical application, photo-
therapy may prove a useful adjunct. The most effective ultraviolet 
(UV) B wavelength for treatment (311–313 nm) has been known 
for more than 30 years.27 Despite this, it is only recently that 
delivery of narrow band UVB has been possible on a widespread 
basis. It is slightly less effective than psoralen (P)UVA in clinical 
trials although is significantly easier to deliver.28
Systemic therapy
Selection of systemic therapy is currently based on physi-
cian experience, relevant past medical history and patient 
choice. It is increasingly clear that psoriasis is a genetically 
heterogeneous group of cutaneous diseases with a similar 
phenotype. Clearer characterization of psoriasis phenotype, 
genotype, co-morbidities and the risk of adverse events from 
therapies should yield a clearer strategy for treatment in the 
future.29 Recent studies have demonstrated that early treatment 
of psoriatic arthritis may offer the opportunity to reduce the 
risk of joint deformity and progressive disability.30 Whilst 
this review includes baseline screening for biological therapy 
it should be remembered that consideration of infection and 
malignancy is mandatory for all systemic agents that are 
immunosuppressive.
Methotrexate
Generally regarded as the gold standard in managing pso-
riasis; methotrexate is well tolerated, efficacious, and can 
be used long term. It is also effective in treating psoriatic 
arthritis. Early clinical trials suggested that more than 60% 
of patients will achieve a psoriasis and area severity index 
(PASI) 75.31,32 More recently two comparative studies have 
shown significantly lower PASI 75 scores of 24% and 36% 
for the methotrexate arm of the study.33,34 These studies were 
carried out over 12 and 16 weeks respectively and may be 
lower due to a delayed onset of action and cautious dose 
incrementation.
A major limitation in therapy is liver toxicity. Historically a 
liver biopsy was recommended after 1.5 gm therapy, or sooner 
as directed by blood monitoring.35 The monitoring of procol-
lagen III peptide (PIIINP) has resulted in some institutions 
recommending liver biopsy only when persistently elevated.36 
The advent of fibroscans, an ultrasound assessment of liver 
elasticity or stiffness, may prove a useful adjunct to PIIINP 
and further rationalize the use of liver biopsy.37
Cyclosporine
Cyclosporine is a widely used alternative to methotrexate, 
providing rapid and reliable improvement in psoriasis for 
up to 80%–90% of patients.38,39 Several further comparative 
studies have demonstrated a good response to treatment 
with PASI 75 achieved in approximately 50%–70%.32,33,40–42 
Whilst highly effective the use of cyclosporine is limited 
by side effects including hypertension and renal impair-
ment. Current guidelines typically recommend short course 
therapy for up to 12 weeks where possible.43 Despite this 
several studies have shown efficacy and safety with long 
term treatment.44,45
retinoids
Retinoids have proved a useful alternative in the treatment 
of psoriasis for over 20 years. Acitretin is a useful option in 
managing individuals with concomitant chronic infection or 
malignancy given that it does not induce immunosuppres-
sion. Retinoids demonstrate efficacy in a select cohort with 
response rates of approximately 40%.46 Research indicates 
acitretin is particularly useful in erythrodermic and pustular 
psoriasis.47Clinical, Cosmetic and Investigational Dermatology 2010:3 28
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Acitretin may be combined with UV therapy, limiting 
the amount of UV required and reducing carcinogenic 
risk of phototherapy.48 A consensus conference in 2004 
determined that combination therapy with acitretin and 
phototherapy is an underutilized therapeutic option that 
is both safe and effective.49 Current recommendations 
advise introduction of phototherapy 2 weeks after initiat-
ing acitretin.18
Studies have demonstrated that retinoids block the action 
of the vascular endothelial growth factor (VEGF) gene and 
that VEGF genotype may have a predictive role in predicting 
response to acitretin therapy in patients with Type 1 chronic 
plaque psoriasis.50,51
Fumaric acid esters
In the UK fumaderm remains an unlicensed agent in the 
treatment of psoriasis. In Europe, and more particularly 
Germany, it has proven a highly effective alternative 
therapy for more than 40 years.52 It is thought to work via 
inhibition of nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB) and inducing apoptosis of 
T-cells.53
The main limitation to treatment is the side effect pro-
file. The principle side effect is gastrointestinal upset, with 
patients reporting: nausea; vomiting; abdominal pain; diar-
rhea and flushing.54 This can be limited by an incremental 
dosing regimen over several weeks. Fumaric acid esters 
provide another alternative where immunosuppression is 
particularly contraindicated. Where tolerated, fumarates 
demonstrate results comparable to methotrexate and 
ciclosporin.55,56
Biological therapies
Biological therapy has developed at a remarkable rate with 
indications for a range of diseases within gastroenterology, 
rheumatology, dermatology, oncology and ophthalmology. 
Biologic agents are proteins that possess pharmacologic 
activity and can be extracted from animal tissue or, much 
more commonly, synthesized in large quantities through 
recombinant DNA techniques. Biologic molecules can 
be designed to either mimic the actions of normal human 
proteins or to interact with circulating proteins or cellular 
receptors. The following discussion covers the routinely used 
biological therapies and newer agents under development 
with reference to indication, safety, and efficacy.
Indication
The point of initiation of biological therapy will depend 
on local guidelines and financial constraints. As with any 
systemic agent, moderate to severe disease (BSA  10%, 
or PASI  10) or disease with high functional or cosmetic 
impact, would justify biological therapy.
Table 1 Baseline investigations prior to biological therapy and during follow up. (adapted from British Association of Dermatology 
Guidelines)
Investigation Pre-treatment Monitoring
PASI Yes To assess response and 6 monthly thereafter
DLQI Yes To assess response and 6 monthly thereafter
Full History (Joint involvement, Chronic Infection,  
Cardiovascular status, Neurological disease, Malignancy)
Yes At review
FBC Yes 3 monthly, then 6 monthly
Renal profile Yes 3 monthly, then 6 monthly
Liver function tests Yes 3 monthly, then 6 monthly
Hepatitis B Yes Periodically in at risk groups
Hepatitis C Yes Periodically in at risk groups
HIv Yes; in at risk individuals Periodically in at risk groups
TB As per BTS guidelines Annual interferon gamma release assay
Autoantibodies (ANA, dsDNA) Yes As indicated by LFT’s or other symptoms of autoimmunity
Urine analysis Yes Not routinely
Urine pregnancy test Yes Periodically in susceptible groups
*Chest X-ray Yes As clinically indicated
Notes: *Likely to be included in new guidelines.
Abbreviations: ANA, antinuclear antibody; dsDNA, double stranded deoxyribonucleic acid; HIV, human immunodeficiency virus; LFT, liver function test; BTS, British Thoracic 
Society; FBC, full blood count; TB, tuberculosis; DCQI, dermatology life quality index; PASI, psoriasis area severity index.Clinical, Cosmetic and Investigational Dermatology 2010:3 29
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Baseline investigations
Prior to commencing biological therapy a full history, exami-
nation and set of baseline investigations are required. Whilst 
no specific investigations have clearly been identified, the 
British Association of Dermatologists have issued guidance 
advising initial investigations to include: PASI, Dermatology 
Life Quality Index (DLQI); full blood count (FBC); renal 
profile; liver function test; antinuclear antibody; Hepatitis B 
and C serology; urine analysis and chest X ray as a minimum 
(Table 1).57 Assessment for tuberculosis is mandatory for all 
patients being considered for biological therapy. This will 
depend on the individual risk of the patient and local guide-
lines. Within the US a consensus statement comprehensively 
reviews this issue.58
Biological therapies are usually avoided through preg-
nancy although small studies to date have not revealed sig-
nificant problems.19 Current guidelines indicate withdrawal 
of biological therapy preoperatively so as to minimize the 
risk of surgical infection and post-operative complication.57 
Timing of this withdrawal should be 4–5 half-lives prior to 
surgical intervention.59
Immunization is generally advised prior to commenc-
ing treatment. The use of live vaccines (varicella, mumps, 
measles, rubella, oral typhoid and yellow fever) and live 
attenuated vaccines (intranasal influenza and herpes zoster) 
should be avoided once therapy is commenced.60,61 Work 
on immune responses to patients receiving biological 
therapy suggests that an adequate, albeit reduced, response 
is observed.62,63 This has become particularly pertinent in 
light of the current swine flu pandemic.
Tumor necrosis factor (TNF) α 
antagonists
By far the most well characterized group of biological thera-
pies are the TNFα antagonists (etanercept, adalimumab and 
infliximab). TNFα is an inflammatory cytokine produced by 
numerous cells including T cells and keratinocytes. TNFα 
is cleaved from a transmembrane bound precursor, from 
where it binds a TNFα receptor. The binding of TNFα to 
its receptor results in downstream activation of the inflam-
matory cascade via NFκB. Blockade of this pathway results 
in down regulation of the inflammation with marked clinical 
improvement.
etanercept
A recombinant human TNFα receptor protein (p75) fused 
with the Fc portion of IgG1, etanercept binds both soluble 
and membrane bound TNFα.64 Etanercept is efficacious 
in treating psoriasis and psoriatic arthritis. Phase III trials 
employing two treatment arms, 25 mg twice weekly and 
50 mg twice weekly, showed a PASI 75 of 34% and 48% 
respectively at week 12.65–67 Etanercept has a slow onset of 
action and therapeutic benefit may be observed beyond this 
12 week time point.67 The impact of etanercept on QoL is 
also demonstrated in reduced scores of depression.68 Whilst 
continuous therapy achieves greater efficacy at 24 weeks than 
interrupted therapy (71% versus 59%), interrupted therapy 
remains a well described and effective option in managing 
chronic plaque psoriasis.66
Combination therapy: Concomitant 25 mg etanercept 
once weekly and acitretin (0.4 mg/kg) was shown to be as 
effective as etanercept 25 mg twice weekly in a small study 
(n = 60).69 Another small study (n = 59) of patients estab-
lished on methotrexate, although not achieving a satisfactory 
control, were further treated with etanercept (25 mg twice 
weekly). Comparison was then made between continuous 
methotrexate versus gradual withdrawal of methotrexate. 
This showed a Physicians’ Global Assessment of clear, 
or almost clear, in 67% and 37% for the “etanercept with 
continuous methotrexate” compared to “etanercept and 
withdrawal of the methotrexate” groups respectively.70 Whilst 
combination therapy with methotrexate and etanercept is 
established in rheumatoid arthritis evidence to support its 
use in psoriasis requires further research.71,72
Etanercept has been shown to be effective and safe in 
children aged 4–17 years of age.73 PASI 75 was achieved 
in 57% of patients treated with etanercept 0.8 mg/kg after 
12 weeks.73
The choice of regimen employed (25 mg or 50 mg twice 
weekly) will be dictated by disease severity, patient weight 
and funding agreements. Other considerations may be in 
the context of chronic infections where minimal effective 
immunosuppression may be desirable.
Clinical practice in rheumatological disease differs in the 
use of etanercept, with regular concomitant methotrexate ther-
apy. There is a small body of evidence indicating that this may 
reduce treatment failure rates in patients with psoriasis.70
Infliximab
A murine and human chimeric antibody, infliximab binds 
avidly to soluble, bound and transmembrane TNFα. It is 
useful in the treatment of psoriasis and psoriatic arthritis. A 
phase III trial, the European Infliximab for Psoriasis Efficacy 
and Safety Study (EXPRESS), of infliximab at a dose of 
5 mg/kg at 0, 2 and 6 weeks followed by 8 week maintenance 
therapy achieved PASI 75 in 82% of patients at week 24.74 Clinical, Cosmetic and Investigational Dermatology 2010:3 30
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Response to treatment is remarkable with clinical improve-
ment within 2 weeks of treatment induction. The efficacy of 
infliximab drops off in a subgroup of patients, at 1 year when 
approximately 61% of patients achieve PASI 75.74,75 Main-
taining response to therapy would appear to correlate with a 
detectable trough serum infliximab level.74 Studies suggest that 
greater numbers of patients achieve PAS175 when receiving 
continuous treatment compared with intermittent therapy.75 This 
improvement in clinical symptoms translates into an improved 
quality of life.76 Furthermore, treatment with infliximab has 
been shown to improve productivity and work attendance.77
Management of nail involvement is a challenging aspect 
of psoriasis. The EXPRESS study demonstrated a 56% 
improvement in nail psoriasis severity index (NAPSI) when 
treated with infliximab.74 It is recommended that infliximab 
be initiated as per the EXPRESS study (5 mg/kg at week 
0, 2 and 6) and then maintained on an 8 weekly infusion 
regimen.
Adalimumab
A fully humanized monoclonal antibody directed against 
TNFα, adalimumab binds both soluble and membrane-
bound forms. It is used in the treatment of both psoriasis 
and psoriatic arthritis. A phase III trial of adalimumab, given 
initially as an 80 mg subcutaneous dose followed by 40 mg 
the following week and then every other week thereafter, 
achieved a PASI 75 of 71% at 16 weeks.78 Further trials, 
including the phase III Comparative Study of Adalimumab 
versus Methotrexate versus Placebo in Psoriasis Patients 
(CHAMPION) study, have revealed similar levels of effi-
cacy.34,79 The improvement in clinical disease has been 
shown to be accompanied by significant improvement in 
health related QoL; comparable to that of the background 
population.80
Similar to other TNFα antagonists, adalimumab is 
maintained long term. Stopping treatment can result in 
reduced efficacy when restarted.78 It is recommended that 
adalimumab be initiated as per the CHAMPION study at 
80 mg week 0, followed by 40 mg week 1 and every other 
week thereafter.
Complications of anti-TNFα therapy
The TNFα antagonists are generally well tolerated. A review 
of relevant studies demonstrated monthly withdrawal rates 
due to adverse events of 0.4% for etanercept, 1.3% for 
infliximab, and 0.3% for adalimumab. 81 monthly serious 
adverse incidents were noted in 0.6% for etanercept, 1.1% 
for infliximab and 0.5% for adalimumab.81 However, there are 
a number of well recognized complications and side effects 
associated with TNFα antagonist therapy.
Adverse events following injection/infusion: These are 
relatively common, tend to be self-limiting, although rarely 
require cessation of treatment. Adverse events following 
injection occur in approximately 14% for etanercept and 3% 
for adalimumab whilst infusion reactions were observed in 
3% for infliximab.74,78,82 A recent review paper provides a 
useful guide to managing such reactions.83
Infection
TNFα antagonists act on a central component of the inflam-
matory cascade and form an integral part of host defense 
against infection. Clinical studies indicate a modest increase 
in upper respiratory and cutaneous infection. More serious 
infections are rare although there are several case reports 
of opportunistic infections in such patients, including his-
toplasmosis and listerosis.84,85 These have largely been in 
the context of rheumatological disease treated with several 
immunosuppressive agents. In the context of serious or active 
infection biological therapy should be withheld.
Patients who have chronic infection require careful 
evaluation on a case by case basis, weighing up potential 
benefits and pitfalls of treatment. Hepatitis C is unusual 
in that hepatic damage is driven by cytotoxic T cell injury 
with associated high levels of TNFα. Consequently, TNFα 
antagonists have been used in limited numbers of patients 
without serious complication.86 By contrast, hepatitis B 
viral replication is controlled by TNFα. TNFα antagonists 
have the potential for reactivation of latent hepatitis B and 
hepatic injury.87 A review of hepatitis B management, with 
reference to immunosuppression, has been issued by the 
American Association for the Study of Liver Disease.88 
A recent review of 8 patients with inactive Hepatitis B 
treated with a TNFα antagonist suggest that prophylactic 
antiviral therapy is indicated even where ALT/AST levels 
are normal.89 All cases of biological therapy in the context 
of chronic infection should be jointly managed with input 
from a relevant specialist.
Tuberculosis (TB) 
Tuberculosis (TB) is a well recognized complication of TNFα 
antagonist therapy. This probably represents both new infec-
tion and reactivation of latent TB. TNFα plays a central role 
in granuloma formation and inhibition of this cytokine has 
the clear potential for granuloma breakdown, disseminating 
mycobacterial infection.90 This risk may be more pronounced 
with monoclonal antibodies to TNFα (adalimumab and Clinical, Cosmetic and Investigational Dermatology 2010:3 31
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infliximab) over etanercept. The development of TB in the 
context of such patients has seen a significantly greater pro-
portion of atypical infection.91,92 A high index of suspicion 
is therefore required with all patients being treated with 
biological therapy given the combination of immunosup-
pression and atypical disease.
Prior to initiating therapy individuals should be assessed 
for possible latent TB. Assessment guidelines are variable 
depending on country of practice. The role of tuberculin tests 
and interferon gamma release assay remain contentious due 
to their sensitivity and specificity in the context of immuno-
suppression. This issue has been comprehensively addressed 
via a US consensus statement.58
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) and biological therapy 
should be considered with extreme caution. The safety of 
treating HIV positive patients is unknown but given that 
both have immunosuppressive effects the risks of adverse 
outcomes may be considerable. Despite this, there are case 
reports of TNFα antagonist therapy in rheumatological 
disease in patients who are HIV positive without significant 
problems developing.93
Neurological diseases
TNFα antagonists are associated with development or wors-
ening of demyelinating disorders, notably multiple sclerosis 
(MS).19 A personal medical history or first degree relative 
affected by MS is a contraindication to treatment with TNFα 
antagonists. Withdrawal of the TNFα antagonist may result in 
resolution of neurological disease in the event of symptoms 
suggestive of demyelination. In all such cases specialist 
neurological opinion is advised.
Heart disease 
The use of biological therapy in the context of inflammatory 
disease has shown conflicting data with improved cardiovas-
cular function in some studies whilst worsening in others. 
A review of 47 case reports of heart failure whilst using 
biological therapy provides some evidence of a causative 
link.94 Conflicting with this review, clinical trials of TNFα 
antagonists in the context of rheumatoid arthritis have failed 
to identify this risk.95 Patient selection excluded known heart 
failure and therefore by definition has a selection bias.
Due to the concern over TNFα antagonists in the context 
of heart failure it is recommended that treatment be avoided 
in patients with New York Heart Association cardiac failure 
Class III or IV (breathless at rest or minimal exertion).19
Drug-induced lupus
Following treatment with the TNFα antagonists has been 
reported in several case studies to date.96 This has been 
observed in a small number of cases and is frequently revers-
ible. There are case reports of therapeutic benefits in patients 
with lupus treated with a biological therapy.97
Malignancy
Early analysis of TNFα antagonists in managing rheuma-
toid arthritis identified an 11.5 fold risk of lymphoma.98,99 
Subsequent inclusion in a larger registry resulted in no such 
relative risk identified.99 These studies failed to identify a risk 
of solid organ malignancy. In contrast to this a meta-analysis 
of 9 clinical trials involving TNFα antagonists identified an 
odds ratio for malignancy of 3.3.100 The risk was greater 
with high dose treatment. A subsequent review of 6 national 
registries has not identified a significant risk of lymphoma or 
solid organ malignancy amongst patients treated with TNFα 
antagonists.101
A recent systematic review of thirty six randomized con-
trolled trial (RCTs) revealed that 26% of cancer diagnoses 
in the treatment arm occurred within the first 12 weeks of 
therapy and raise a significant question as to baseline screen-
ing.102 These results require further evaluation; data registries 
will help address this.
The risk of cutaneous malignancy remains an area requir-
ing further study. A study of 1,442 patients with rheumatoid 
arthritis treated with etanercept failed to establish a link 
with squamous cell carcinoma whilst in a larger study of 
13,001 patients with rheumatoid arthritis, 49% of which 
were exposed to a biological therapy, indicated a modest 
increased rate of both melanoma and non-melanoma skin 
cancer.103,104
Alefacept
Alefacept, used widely in the United States (US), has no 
European license for the treatment of psoriasis. Consisting 
of the extracellular cluster of differentiation (CD)-2 bind-
ing portion of lymphocyte function associated antigen-3 
(LFA-3), linked to the Fc portion of human immunoglobulin 
(Ig) G1, its mode of action is thought to be mediated by 
selective depletion of memory effector (CD45RO+) T lym-
phocytes.105 Phase III trials of alefacept given weekly at a 
dose of 15 mg/kg demonstrated PASI 75 in 21% of patients 
at week 14.106–108
Alefacept therapy necessitates CD4 lymphocyte count 
prior to commencing therapy and every other week thereafter. Clinical, Cosmetic and Investigational Dermatology 2010:3 32
Laws and Young Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Treatment should be withheld when CD4 counts drop below 
250 cells/mL. Due to the impact on CD4 count, HIV and 
high risk of malignancy or infection exclude alefacept as 
an option for therapy in such patients. Whilst not routinely 
used to manage psoriatic arthritis limited data indicates it 
is effective.109
Alefacept has generally been well tolerated in clinical 
trials. Adverse events following injection are reported, par-
ticularly chills, which are self limiting and did not necessitate 
withdrawal of therapy.
efalizumab
Efalizumab is included in this section given its proven role 
in treating psoriasis despite its global withdrawal. It is a 
recombinant monoclonal IgG1 antibody directed against the 
CD11a subunit of LFA-1. LFA-1 is central to T-cell adhesion 
and migration through endothelial wall and into inflamed 
skin.110,111 It is also involved in reactivation of T cells.112 
Phase III trials, including the Clinical Experience Acquired 
with Raptiva (CLEAR) study, revealed a PASI 75 response 
of up to 39%.113–117 Efalizumab is not effective in treating 
psoriatic arthritis.118
Due to case reports of progressive multifocal leuko-
encephalopathy (PML) in three patients receiving efali-
zumab for chronic plaque psoriasis this treatment option 
has been withdrawn globally.119 This complication of 
impaired immune surveillance is not unique to efalizumab. 
Natalizumab, a very late antigen (VLA)-4 antagonist, used 
in treating multiple sclerosis, has also been reported in 
association with PML. Both efalizumab and natalizumab 
affect T cell migration which is thought to underlie the 
susceptibility to PML.120
Ustekinumab
Interleukin (IL) 12 and IL23 share an homologous subunit, 
p40. Ustekinumab is an IL12/23 monoclonal antibody 
directed against this shared p40 subunit. IL12 is a key 
cytokine directing the differentiation of T cells into a T 
helper lymphocyte (Th)-1 phenotype.121 IL23, a member 
of the IL12 family, stimulates naïve T cell differentiation 
toward a Th17 phenotype.122 IL12/IL23 has a central role 
in the adaptive response involved in the pathogenesis of 
psoriasis.123
Phase III clinical trials for ustekinumab, including PHOE-
NIX I and II, demonstrated 67% and 72% achieve a PASI 75 
after 12 weeks with either 45 mg or 90 mg respectively.124–126 
Ongoing improvement may be seen up to 24 weeks after 
commencing treatment.
The injection was well tolerated with serious adverse 
events in 4% compared to 1% for the placebo group. It is 
also effective in treating psoriatic arthritis.127 As an upstream 
inhibitor of TNFα it may be expected that the risk profile of 
ustekinumab may be broadly similar.
Data registry
Biological therapies are an emerging treatment option for a 
range of disease in dermatology. Safety profiles to date have 
been promising with relatively few serious adverse outcomes. 
However, concerns remain over the long term safety of these 
agents. With pharmacovigilance a high priority, several 
countries including: France; Italy; Spain; Sweden; Germany, 
and the United Kingdom have established data registry’s. The 
British Society of Rheumatology Biologics Register (BSRBR) 
have recently reported initial results which to date have identi-
fied a modest rise in cutaneous infection;128 a reduced risk of 
myocardial infarction;129 but no major increased risk of fetal 
abnormality or spontaneous abortion in patients with rheuma-
toid arthritis treated with TNFα antagonists.130 Caution must 
be exercised in extrapolating data from this register since the 
underlying disease may influence outcomes.
The future of psoriasis  
and biological therapies
As our understanding of the immunopathogenesis of psoria-
sis grows so does the opportunity for development of new 
therapeutic targets. New and emerging options for biological 
therapy include the TNFα blocking monoclonal antibodies 
(certolizumab and golumimab) and targets of the IL-12/23 
pathway (ABT-874). In addition to the development of new 
biological therapies a number of small molecules show promise 
of delivering new therapeutic options in managing psoriasis.
Certoluzimab-pegol
This fragment antigen binding (Fab) portion of human 
TNFα has been shown to be effective in the treatment of 
Crohn’s disease and rheumatoid arthritis; and may therefore 
prove efficacious in the treatment of psoriasis.131 Due to the 
absence of the fragment crystallizable (Fc) region, activa-
tion of complement and antibody-dependent cell mediated 
cytotoxicity does not occur in-vitro.132
Golimumab
A phase III trial of golimumab treated for psoriatic arthritis 
given 50 mg monthly in a placebo controlled study involv-
ing 405 patients indicated 40% of patients achieve a PASI Clinical, Cosmetic and Investigational Dermatology 2010:3 33
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75 at 14 weeks.133 Care must be used in interpreting this data 
since pre-intervention PASI scores are likely to be lower, 
and hence less sensitive, than patients entering clinical trials 
for cutaneous disease only. The Golimumab-Randomized 
Evaluation of Safety and Efficacy in Subjects with Psoriatic 
Arthritis Using a Human Anti-TNF Monoclonal Antibody 
(GO-REVEAL) study demonstrated a similar efficacy in 
treating psoriatic arthritis.
Briakinumab
Briakinumab, previously known as ABT-874, is a p40 
monoclonal antibody, with a similar mechanistic action 
to ustekinumab. Phase 2 trials of briakinumab, involving 
180 patients, were randomized to 6 different treatment arms. 
After 12 weeks, PASI 75 was achieved in 63% to 93%, 
depending on which treatment arm was being reviewed.134
Fezakinumab
IL 22 is a key cytokine produced by Th17 cells which has 
been shown to induce dermal inflammation and acanthosis.135 
This provides a link between adaptive immunity and epithe-
lial dysfunction.136 Fezakinumab is a monoclonal antibody 
directed against IL 22 which has registered to undergo phase I 
clinical trials.
AIN-457
IL 17, an integral part of the psoriatic inflammatory cas-
cade, has recently been linked to successful treatment with 
etanercept.137 The specificity of IL-17 inhibition raises the 
possibility of it providing a further therapeutic target in man-
aging psoriasis.137 Current work on a phase II clinical trial in 
psoriatic arthritis is likely to provide evidence of potential 
therapeutic benefit in cutaneous disease.
Small molecules
Small molecules are a diverse group of organic compounds 
which by definition have a low molecular weight. An ever 
increasing number of molecules have registered patents. 
These have been recently reviewed.138 Most of these drugs act 
on an intracellular target and modify intracellular signaling. 
Some examples are reviewed below.
voclosporin
Cyclosporin provides reliable and effective treatment for 
psoriasis. The limitations of treatment, namely nephrotoxicity 
and hypertension, frequently limit use. A newly developed 
calcineurin inhibitor, voclosporin, recently underwent phase 
3 clinical trials. PASI 75 was achieved at 12 weeks in 16%, 
25% and 47% for the 0.2 mg/kg, 0.3 mg/kg and 0.4 mg/kg 
groups respectively.139 This study emphasized a strong 
correlation with serum drug concentration, raising the pos-
sibility of enhanced efficacy and reduced toxicity.
Janus kinase (JAK) 3 inhibitors
Janus kinase (JAK) 3 inhibitors are signal transducers 
and activators of transduction (STAT) inhibitors. JAK3 
is a protein tyrosine kinase which forms a key intracel-
lular signal transduction point for a proinflammatory 
signal from γ-chain receptors, relevant to cytokines 
IL-2, -4, -7, -9, -15 and -21.140 Activation of JAK3 leads 
to phosphorylation of STAT which then translocates to 
the nucleus where it modifies gene transcription.141 CP-
690,550 is an oral JAK3 inhibitor which has recently 
entered phase II clinical trials and has shown significant 
improvement in psoriatic plaque severity.142 Further stud-
ies with CP-690,550 are ongoing.
Conclusions
Psoriasis is a common disease which carries a significant 
physical and psychological burden. The impact of the disease 
is that it not only affects the patient but has implications on 
health economics. Understanding and treatment for psoriasis 
and psoriatic arthritis has moved forward greatly over the 
last few years. The identification of subtle differences in 
psoriasis phenotypes, pathogenesis and immunobiology will 
drive forward our understanding of disease and will provide 
new options to control the disease.
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